Robert Alan Seder, M.D.
Cellular Immunology Section
4 Memorial Drive, Room 228B
Bethesda, MD 20814
The aim of the Cellular Immunology Section (CIS) is to provide a mechanistic basis for developing vaccines for diseases that require humoral and cellular immunity. The specific focus is on preventive vaccines against HIV, malaria and tuberculosis and therapeutic vaccines against cancer.
Based on the critical role of CD4 and CD8 T cells in mediating protection against infections and tumors, a major area of study is to understand how various vaccine platforms influence the magnitude, quality, breadth and tissue distribution following immunization. This work uses recombinant viral, protein/adjuvant, and attenuated whole organism approaches. T-cell responses are assessed with a variety of technologies including multi-parameter flow cytometry, microfluidics (Fluidigm), and RNAseq. To understand the cellular and molecular mechanisms by which vaccines and immune adjuvants influence T cell immunity in vivo, we study the tropism of the vaccines or adjuvants for specific dendritic cell subsets and combine this with a global assessed of innate immunity by gene profiling.
The laboratory has a major focus on determining how different immune adjuvants influence humoral and cellular immunity when administered with protein or peptide antigens. Recent work has focused on using polymer chemistry and other bio-engineering approaches with specific toll-like receptor ligands (TLR) to optimize the delivery HIV, RSV or FLU protein antigens to optimize antibody responses and tumor specific neo-antigens to enhance T cell immunity.
Translation: To show how the different vaccines approaches mediate protection, experimental mouse and nonhuman primate models of infections such as Leishmania major, Mycobacterium tuberculosis, Listeria monocytogenes, malaria, and HIV/SIV infection are used. Moreover, we recently showed that an attenuated whole sporozoite malaria vaccine confers long-term protection in humans in a small number of subjects. Ongoing work is determining the immune correlates and mechanism of protection. This work is now being extended to a Phase II efficacy trial in African infants.
Dr. Seder received his B.A. in Natural Science at Johns Hopkins University in 1981 and his M.D. at Tufts University in 1986, and completed his residency in internal medicine at New York Hospital-Cornell Medical Center. Dr. Seder did his postdoctoral training at NIAID with Dr. William Paul studying how cytokines influence CD4+ T helper cell differentiation.
In 1994, Dr. Seder became Chief of the Clinical Immunology Section in the Laboratory of Clinical Investigation, part of the NIAID Division of Intramural Research.Dr. Seder was then appointed to a tenured position in the Vaccine Research Center (VRC), Laboratory of Immunology in 2000. Since joining the VRC, Dr. Seder has focused his efforts on understanding the innate and adaptive mechanisms by which various vaccines approaches mediate protective antibody and T cell immunity in mouse, non-human primate and human models of HIV, Malaria and Tuberculosis infection. Dr. Seder is internationally recognized in the field of vaccine biology and cellular immunology. He currently serves as chief of the Cellular Immunology Section in the VRC.
Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science. 2011;334(6055):475-80.
Kastenmüller K, Wille-Reece U, Lindsay RW, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, Kaplan DH, Kastenmüller W, Germain RN, Seder RA. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest. 2011;121(5):1782-96.
Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, VRC 312 Study Team.. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359-65.
Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007;13(7):843-50.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on February 8th, 2017